Periodontal Disease and Post-menopausal Osteoporosis
"Levels of RANKL and OPG in Gingival Crevicular Fluid of Patients With Post-menopausal Osteoporosis / Osteopenia and Periodontal Disease."
2 other identifiers
observational
81
1 country
1
Brief Summary
The aim of this study was to investigate the levels of RANKL and Osteoprotegerin, and their relationship in gingival crevicular fluid of post-menopausal women with osteoporosis/osteopenia and chronic periodontitis simultaneously and evaluate the effect that the use of bisphosphonates in periodontal disease. Study hypothesis: "The osteoporosis / osteopenia in postmenopausal women patients with periodontal disease affect the ratio RANKL / OPG in gingival crevicular fluid samples favoring osteoclastogenesis processes "
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2012
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2013
CompletedFirst Submitted
Initial submission to the registry
July 3, 2014
CompletedFirst Posted
Study publicly available on registry
July 9, 2014
CompletedJuly 9, 2014
July 1, 2014
1.3 years
July 3, 2014
July 8, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
levels of RANKL and OPG
one year
Eligibility Criteria
Patients with osteopenia / osteoporosis and controls with normal osseous condition. Both groups with chronic periodontitis
You may qualify if:
- Women between 45-70 years with Absorptiometry Dual Energy X-ray (DEXA).
- Control group: post-menopausal women with periodontal disease and normal osseous condition.
- Study group: post-menopausal womens with periodontal disease and osteoporosis/osteopenia with and without bisphosphonate treatment (risedronate or ibandronate 150 mg) for longer than 3 months before the study and another.
You may not qualify if:
- Patients with history of aggressive periodontitis and had received any periodontal treatment when they entered the study
- Patients with any systemic illness (except osteopenia/osteoporosis)
- Patients who received antibiotic or non-steroidal anti-inflammatory therapy in the 6 months prior to the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Facultad de Odontología - Universidad Nacional de Córdoba
Córdoba, Córdoba Province, 5000, Argentina
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
María E Verde, Odontóloga
Facultad de Odontología - UNC
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- María Eugenia Verde - Cátedra de Periodoncia A - UNC
Study Record Dates
First Submitted
July 3, 2014
First Posted
July 9, 2014
Study Start
May 1, 2012
Primary Completion
September 1, 2013
Study Completion
September 1, 2013
Last Updated
July 9, 2014
Record last verified: 2014-07